miR-622 Suppresses Tumor Formation by Directly Targeting VEGFA in Papillary Thyroid Carcinoma [Retraction]
Wang R, Ma Q, Ji L, Yao Y, Ma M, Wen Q. Onco Targets Ther. 2018;11:1501—1509.
The Editor and Publisher of OncoTargets and Therapy wish to retract the published article. The journal was notified of alleged image manipulation relating to Figure 3B. Specifically:
- Figure 3B panel miR-NC appears to be a duplication, but with more cells added, of Figure 7B panel si-CON group published in Wang et al, 2017 (https://doi.org/10.1159/000480412).
- The same image has also been observed in other publications, including Figure 11a panel miR-708 mimic, published in Song et al, 2019 (https://doi.org/10.1007/s12253-017-0334-z) and in Figure 8B published in Pan et al, 2018 (RETRACTED) (https://doi.org/10.1159/000487567).
The authors were unable to provide a satisfactory explanation for the duplication and the decision was made to retract the paper.
Our decision-making was informed by our policy on publishing ethics and integrity and the COPE guidelines on retraction.
The retracted article will remain online to maintain the scholarly record, but it will be digitally watermarked on each page as “Retracted”.
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF]